Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 5037-5048

  Mekkawy, Ahmed H ^a   Pourgholami, Mohammad H ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adhesion; Breast cancer; Invasion; Migration; Proliferation; Sprouty; VEGF

Indexed keywords

COLLAGEN TYPE 4; MATRIGEL; SPROUTY PROTEIN; SPROUTY PROTEIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN; MEMBRANE PROTEIN; PHOSPHOPROTEIN; SPRY1 PROTEIN, HUMAN; VASCULOTROPIN A;

ADHESION; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 231 CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; T47D CELL LINE; BREAST TUMOR; CELL MOTION; FEMALE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; FEMALE; HUMANS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902970141     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1665-y     Document Type: Article

References (36)

1. Hacohen N et al. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998;92(2):253-63. (Pubitemid 28073048)
2. Tefft JD et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol. 1999;9:219-22. (Pubitemid 29120388)
3. Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 1999;96(5):655-65. (Pubitemid 29122808)
4. Sasaki A et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol. 2003;5(5):427-32. (Pubitemid 36592265)
5. Rubin C et al. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol. 2003;13(4):297-307. (Pubitemid 36230020)
6. Impagnatiello MA et al. Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol. 2001;152(5):1087-98. (Pubitemid 34286083)
7. Gross I et al. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001;276(49):46460-8.
8. Lo TL et al. The Ras/Mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Res. 2004;64:6127-36. (Pubitemid 39129413)
9. Kwabi-Addo B et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004;64:4728-35. (Pubitemid 38924514)
10. Sirivatanauksorn Yet al. Differential expression of sprouty genes in hepatocellular carcinoma. J Surg Oncol. 2012;105(3):273-6.
11. Fong CW et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66(4):2048-58.
12. Mekkawy AH et al. Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun. 2010;399(4):738-43.
13. Mekkawy AH, Morris DL. Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochem. 2013;2013:7.
14. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
15. Pourgholami MH et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012;125(2):433-40.
16. Mekkawy AH, Morris DL, Pourgholami MH. HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol. 2012;2012:950749.
17. McClay, D.R. and P.L. Hertzler, Quantitative measurement of cell adhesion using centrifugal force. Curr Protoc Cell Biol, 2001. Chapter 9: p. Unit 9 2.
18. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12 Suppl 1:S70-80. (Pubitemid 43385274)
19. Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell. 2000;103(1):13-5.
20. Ozaki K et al. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci. 2005;118(Pt 24):5861-71. (Pubitemid 43084624)
21. Lee S et al. Sprouty1 inhibits angiogenesis in association with upregulation of p21 and p27. Mol Cell Biochem. 2010;338(1-2):255-61.
22. Gross I et al. The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem. 2003;278(42):41420-30. (Pubitemid 37280971)
23. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911-2. (Pubitemid 35425238)
24. Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 2011;716:157-68.
25. Aumailley M, Timpl R. Attachment of cells to basement membrane collagen type IV. J Cell Biol. 1986;103(4):1569-75. (Pubitemid 17174179)
26. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5(5):864-8.
27. Gui GP et al. Altered cell-matrix contact: a prerequisite for breast cancer metastasis? Br J Cancer. 1997;75(5):623-33. (Pubitemid 27091073)
28. Hurt EM et al. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 2010;28(3):390-8.
29. De Bock CE et al. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. Int J Oncol. 2010;36(5):1155-63.
30. Akbulut, S., et al., Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol Biol Cell, 2010
31. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4-10. (Pubitemid 41680947)
32. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795-803. (Pubitemid 37328914)
33. Tang L et al. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food Chem Toxicol. 2013;56:204-13.
34. Yu P et al. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 2009;59(3):219-29.
35. Salva E et al. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo. Nucleic Acid Ther. 2012;22(1):40-8.
36. Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006;12(3):387-94.